View:
Download DOC
Download PDF
Download XLS
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Tross Stuart A
(Last) (First) (Middle)
ONE AMGEN CENTER DRIVE
(Street)
THOUSAND OAKS CA 91320-1799
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/21/2013 		3. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Human Resources
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 22,948(1)(2) D
Common Stock 593.142(3) I 401(k) Plan
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Nqso (Right to Buy) 04/26/2011(4) 04/26/2020 Common Stock 5,060 58.43 D
Nqso (Right to Buy) 04/25/2013(5) 04/25/2021 Common Stock 6,250 54.69 D
Explanation of Responses:
1. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 362 RSUs which fully vest on 4/26/2014; 1,197 RSUs which vest in one installment of 589 on 4/25/2014 and one installment of 608 on 4/25/2015; 1,320 RSUs which vest in three installments of 435, 436 and 449 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 13,958 RSUs which fully vest on 9/1/2014 and 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
2. These shares include 435 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
3. These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
4. 2,530 of these stock options are exercisable immediately and the remaining 2,530 are exercisable on 4/26/2014.
5. 2,062 of these stock options are exercisable immediately and the remaining 4,188 are exercisable in two installments of 2,063 and 2,125 on 4/25/2014 and 4/25/2015, respectively.
/s/ Stuart A. Tross 10/24/2013
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Exhibit 24

Power of Attorney


		Know all men by these presents, that the undersigned hereby
constitutes and appoints each of John C. Ayres, Richard T. Benson and
Andrea A. Robinson, signing singly, the undersigneds true and lawful
attorney-in-fact to execute for and on behalf of the undersigned Forms 3,
4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of
1934, as amended, and the rules thereunder, as may be required as a result
of the undersigneds position as an officer and/or director of Amgen Inc.
(the Company).

		The undersigned hereby grants to each such attorney-in-fact
full power and authority to execute such Forms 3, 4 and 5 as fully to all
intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying
and confirming all that such attorney-in-fact, or such attorney-in-facts
substitute or substitutes, shall lawfully do or cause to be done by virtue
of this power of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not
assuming, nor is the Company assuming, any of the undersigneds
responsibilities to comply with Section 16 of the Securities Exchange Act
of 1934, as amended.

		This Power of Attorney shall remain in full force and
effect until the undersigned is no longer required to file Forms 3, 4
and 5 with respect to the undersigneds holdings of and transactions
in securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.

		IN WITNESS WHEREOF, the undersigned has caused this Power
of Attorney to be executed as of this 17th day of October, 2013.




						/s/   Stuart A. Tross
						Name: Stuart A. Tross